Your browser doesn't support javascript.
loading
High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors
Protein & Cell ; (12): 877-888, 2021.
Article in English | WPRIM | ID: wpr-922482
ABSTRACT
A new coronavirus (SARS-CoV-2) has been identified as the etiologic agent for the COVID-19 outbreak. Currently, effective treatment options remain very limited for this disease; therefore, there is an urgent need to identify new anti-COVID-19 agents. In this study, we screened over 6,000 compounds that included approved drugs, drug candidates in clinical trials, and pharmacologically active compounds to identify leads that target the SARS-CoV-2 papain-like protease (PLpro). Together with main protease (M
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Antiviral Agents / Protease Inhibitors / Binding Sites / Recombinant Proteins / Mutagenesis, Site-Directed / Naphthoquinones / Protein Structure, Tertiary / Crystallography, X-Ray / Inhibitory Concentration 50 / Drug Evaluation, Preclinical Type of study: Diagnostic study / Screening study Limits: Humans Language: English Journal: Protein & Cell Year: 2021 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Antiviral Agents / Protease Inhibitors / Binding Sites / Recombinant Proteins / Mutagenesis, Site-Directed / Naphthoquinones / Protein Structure, Tertiary / Crystallography, X-Ray / Inhibitory Concentration 50 / Drug Evaluation, Preclinical Type of study: Diagnostic study / Screening study Limits: Humans Language: English Journal: Protein & Cell Year: 2021 Type: Article